Argentina Antibody Drug Conjugates Market Size & Outlook
Argentina antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Argentina antibody drug conjugates market highlights
- The Argentina antibody drug conjugates market generated a revenue of USD 12.9 million in 2021 and is expected to reach USD 72.4 million by 2030.
- The Argentina market is expected to grow at a CAGR of 21.1% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 12.9 million |
| Market revenue in 2030 | USD 72.4 million |
| Growth rate | 21.1% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Argentina accounted for 0.2% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 110.4 million by 2030.
Breast cancer was the largest segment with a revenue share of 54.26% in 2021. Horizon Databook has segmented the Argentina antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Although ADC drugs such as MYLOTARG, intended for the treatment of acute myeloid leukemia, have been approved in Argentina as early as 2000, the fragmentation of health services is leading to unequal distribution of health services in different regions, ultimately affecting the level of cancer care provided.
Moreover, lack of national-level planning on cancer, inadequate financial organization, and low-quality services delivered to significant portions of the population have been cited in a 2018 article published by Novartis. Hence, the growth of ADC drugs in Argentina is expected to be slow over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Argentina antibody drug conjugates market size, by application, 2018-2030 (US$M)
Argentina Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
